Advisory Alpha’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Advisory Alpha’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-50	Closed	-$1K	–	704
2020 Q3	$1K	Buy	+50	New	+$458	﹤0.01%	685

Other funds holding SRNE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Advisory Alpha's SRNE Position: Q4 2020 in Review

Advisory Alpha sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2020, closing a stake of 50 shares — an estimated $1K sold.

Advisory Alpha first reported a position in SRNE in Q3 2020 and held it in 1 quarter. The position peaked at $1K in Q3 2020. 219 funds tracked by Wall St. Rank hold SRNE as of Q4 2020.

Advisory Alpha reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
Advisory Alpha sold 50 Sorrento Therapeutics, Inc. shares in Q4 2020, an estimated $1K.
Advisory Alpha first reported a position in Sorrento Therapeutics, Inc. in Q3 2020 and held it in 1 quarter.
Advisory Alpha's Sorrento Therapeutics, Inc. position peaked at $1K in Q3 2020.
219 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2020.

Based on Advisory Alpha's 13F filing for Q4 2020, filed 16 Feb 2021.